Are Comorbidities Related to Frequent Severe Exacerbations of AECOPD

• Sponsor: Ankara University (Other)
• Overall Status: Completed
• CT.gov ID: NCT05504993
• Collaborator: (none)
• Enrollment: 92
• Location: 1
• Actual Duration (Months): 48
• Patients Per Site Per Month: 1.9

Study Details

Study Description

Brief Summary

INTRODUCTION: Relationship between comorbidities and COPD is two-sided. While the number of comorbidities increasing, the frequency of acute exacerbations of COPD (AECOPD) is increasing, too. Comorbidity indexes can be used for recognition of comorbidities while managing COPD patients. In the present study, it is aimed to compare comorbidity indexes such as Charlson Comorbidity Index, COMCOLD and COTE in the matter of exacerbation frequency.

METHOD: Subjects hospitalized for AECOPD, admitted to the study. Exacerbation severity, frequency, further exacerbations for a 1-year period in the follow-up period and CCI, COMCOLD and COTE scores were recorded. High and low comorbidity groups were compared for AECOPD frequency, severity, and further exacerbations.

Condition or Disease	Intervention/Treatment	Phase
Chronic Obstructive Lung Disease; Acute Exacerbation of COPD; Comorbidities and Coexisting Conditions	Other: Frequency of AECOPD

Study Design

• Study Type: Observational
• Actual Enrollment: 92 participants
• Observational Model: Case-Only
• Time Perspective: Cross-Sectional
• Official Title: Are Comorbidities Related to Frequent Severe Exacerbations of AECOPD
• Actual Study Start Date: Jan 1, 2018
• Actual Primary Completion Date: Jul 1, 2018
• Actual Study Completion Date: Jan 1, 2022

Arms and Interventions

Arm	Intervention/Treatment
High comorbidity group CCI equal or higher than 2 COTE equal or higher than 4 COMCOLD equal or higher than 4	Other: Frequency of AECOPD; No intervention has been applied. 92 COPD patients divided into 2 groups according to their comorbidity level. Than these groups were compared for their AECOPD frequency
Low comorbidity group CCI lower than 2 COTE lower than 4 COMCOLD lower than 4	Other: Frequency of AECOPD; No intervention has been applied. 92 COPD patients divided into 2 groups according to their comorbidity level. Than these groups were compared for their AECOPD frequency

Outcome Measures

Primary Outcome Measures

1. Frequency of AECOPD [1 year]

   Frequency of AECOPD in the last one year

Secondary Outcome Measures

1. Having at least one severe AECOPD [1 year]

   having at least one severe AECOPD in the last year

2. Frequency of AECOPD for the next one year [1 year]

   the number of AECOPD for 1 year period from the preceding admission, regardless of severity

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All

Inclusion Criteria:

• COPD patients

• Admitted to the ward for AECOPD

Exclusion Criteria:

• Not giving informed consent

• Unable to perform PFT

• Lost to follow-up

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Ankara University Faculty of Medicine	Ankara		Turkey

Sponsors and Collaborators

• Ankara University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Deniz Doğan Mülazimoğlu, University Lecturer, Ankara University
• ClinicalTrials.gov Identifier: NCT05504993
• Other Study ID Numbers: 05-305-18
• First Posted: Aug 17, 2022
• Last Update Posted: Aug 17, 2022
• Last Verified: Aug 1, 2022

• Individual Participant Data (IPD) Sharing Statement: Undecided
• Plan to Share IPD: Undecided
• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Additional relevant MeSH terms: Lung Diseases; Lung Diseases, Obstructive; Pulmonary Disease, Chronic Obstructive

Study Results

No Results Posted as of Aug 17, 2022